iX Biopharma unit obtains Australia licence to bring product testing in-house
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
IX Biopharma on Monday said it has obtained a licence in Australia to bring its product testing in-house, improving speed-to-market and potentially saving on testing costs.
The pharmaceutical company's wholly-owned subsidiary iX Syrinx obtained a Good Manufacturing Practice (GMP) licence from the Therapeutic Goods Administration of Australia for its testing laboratory located within its facility in Victoria, Australia, it said in a press statement.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
20 photos that show how dramatically Singapore has changed in two decades
Singapore’s key exports up 15.3% in March from electronics surge, exceeding forecasts
